MedTrace Logo

A First Time In Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK1399686

NCT00721812 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 87

Last updated 2017-07-07

No results posted yet for this study

Summary

A First-Time-in-Human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of GSK1399686 After Single and Repeated Oral Dosing in Healthy Volunteers

Conditions

  • Inflammatory Bowel Diseases

Interventions

DRUG

GSK1399686

Safety and tolerability dose escalation in normal human volunteers

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-09-25
Primary Completion
2009-05-27
Completion
2009-05-27

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00721812 on ClinicalTrials.gov